Pandion Therapeutics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pandion Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pandion Therapeutics stock.
View analyst ratings for Pandion Therapeutics or view top-rated stocks.

Wall Street analysts have given Pandion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pandion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Pandion Therapeutics saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 483,700 shares, an increase of 50.1% from the January 28th total of 322,200 shares. Based on an average trading volume of 116,700 shares, the days-to-cover ratio is currently 4.1 days. Approximately 4.1% of the shares of the company are short sold.
View Pandion Therapeutics' Short Interest.

Pandion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Pandion Therapeutics.

Pandion Therapeutics, Inc. (NASDAQ:PAND) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.07. The firm earned $2.63 million during the quarter, compared to the consensus estimate of $1 million.
View Pandion Therapeutics' earnings history.

4 brokerages have issued twelve-month target prices for Pandion Therapeutics' shares. Their forecasts range from $28.00 to $60.00. On average, they anticipate Pandion Therapeutics' share price to reach $44.25 in the next year. This suggests that the stock has a possible downside of 26.1%.
View analysts' price targets for Pandion Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Pandion Therapeutics include Sarepta Therapeutics (SRPT), GW Pharmaceuticals (GWPH), Allakos (ALLK), Maravai LifeSciences (MRVI), Evotec (EVTCY), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Galapagos (GLPG), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR), Emergent BioSolutions (EBS), Schrödinger (SDGR) and Sage Therapeutics (SAGE).
View all of PAND's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Moderna (MRNA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Curaleaf (CURLF), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), (NGM) and OPKO Health (OPK).

(PAND) raised $94 million in an initial public offering on Friday, July 17th 2020. The company issued 5,500,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

Pandion Therapeutics trades on the NASDAQ under the ticker symbol "PAND."

Pandion Therapeutics' lock-up period expired on Wednesday, January 13th. Pandion Therapeutics had issued 7,500,000 shares in its IPO on July 17th. The total size of the offering was $135,000,000 based on an initial share price of $18.00. Since the end of Pandion Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Pandion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.71%), BlackRock Inc. (2.38%), Alyeska Investment Group L.P. (0.30%), Alyeska Investment Group L.P. (0.30%), JPMorgan Chase & Co. (0.12%) and Nuveen Asset Management LLC (0.10%). Company insiders that own Pandion Therapeutics stock include Daniel J Becker and Plc Glaxosmithkline.
View institutional ownership trends for Pandion Therapeutics.

PAND stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board.
View insider buying and selling activity for Pandion Therapeutics or view top insider-selling stocks.

PAND stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., JPMorgan Chase & Co., Nuveen Asset Management LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., State of Wisconsin Investment Board, and Wells Fargo & Company MN. Company insiders that have bought Pandion Therapeutics stock in the last two years include Daniel J Becker, and Plc Glaxosmithkline.
View insider buying and selling activity for Pandion Therapeutics or or view top insider-buying stocks.

Shares of PAND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PAND stock can currently be purchased for approximately $59.89.

Pandion Therapeutics has a market capitalization of $1.77 billion and generates $970,000.00 in revenue each year.

Pandion Therapeutics employs 43 workers across the globe.

The official website for Pandion Therapeutics is www.pandiontx.com.

Pandion Therapeutics is headquartered at 134 COOLIDGE AVENUE 2ND FLOOR, WATERTOWN MA, 02472.

Pandion Therapeutics' mailing address is 134 COOLIDGE AVENUE 2ND FLOOR, WATERTOWN MA, 02472. The company can be reached via phone at 617-393-5925 or via email at [email protected]